Physician profile
Ami Patel
NPI 1184357634
$1,682.19
in general payments reported to CMS, 2019-2025
17 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $231 · 2024: $1,156 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.43 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $366.85 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $258.52 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.57 | 2024 | Trulance, Xifaxan, Plenvu |
| Madrigal Pharmaceuticals | $195.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $118.90 | 2023-2024 | Talicia, Aemcolo |
| Janssen Scientific Affairs, LLC | $90.31 | 2023 | Stelara, Remicade |
| Lilly USA, LLC | $63.54 | 2024 | Omvoh |
| Celgene Corporation | $62.82 | 2023 | Zeposia |
| Janssen Biotech, INC. | $61.94 | 2024 | Stelara, Tremfya |
| Celltrion USA INC. | $59.43 | 2024-2025 | Vegzelma |
| Genzyme Corporation | $50.11 | 2024 | |
| Phathom Pharmaceuticals, INC. | $31.72 | 2024 | Voquezna |
| Ardelyx, INC. | $31.27 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $27.26 | 2025 | Rexulti |
| Exact Sciences Corporation | $22.06 | 2025 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.70 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.14 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.